Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fanyan Meng

Showing results (51-60 of 88) with videos related to

Pageof 9
Sort By:
Frontiers in Immunology|December 31, 2025
Tumor-penetrating peptide boosts bispecific T-cell engager antitumor efficacy for the pancreatic cancerLu Zou, Jingjing Chen, Xinyuan Bai, et al.
Frontiers in Oncology|June 21, 2021
Identification of a Glypican-3 Binding Peptide From a Phage-Displayed Peptide Library for PET Imaging of Hepatocellular CarcinomaJiayao Yan, Xiaoxiao Yu, Xiaotong Chen, et al.
Human Vaccines & Immunotherapeutics|February 22, 2023
Biomarkers for predicting tumor response to PD-1 inhibitors in patients with advanced pancreatic cancerXin Qiu, Zhan Shi, Fan Tong, et al.
Materials Today. Bio|June 23, 2022
In situ gelatinase-responsive and thermosensitive nanocomplex for local therapy of gastric cancer with peritoneal metastasisXinyue Wang, Jiahui Gao, Chunhua Li, et al.
Cancer Science|September 19, 2021
Tumor eradicated by combination of imiquimod and OX40 agonist for in situ vaccinationYanhong Chu, Rutian Li, Lingyu Qian, et al.
Journal for Immunotherapy of Cancer|May 14, 2021
Bifunctional iRGD-anti-CD3 enhances antitumor potency of T cells by facilitating tumor infiltration and T-cell activationShujuan Zhou, Fanyan Meng, Shiyao Du, et al.
Cellular Immunology|June 16, 2018
Activation and propagation of tumor-infiltrating lymphocytes from malignant pleural effusion and ascites with engineered cells for costimulatory enhancementQiuping Xu, Jie Shao, Shu Su, et al.
Oncology Reports|January 8, 2021
[Corrigendum] Tumor‑penetrating peptide fused EGFR single‑domain antibody enhances radiation responses following EGFR inhibition in gastric cancerFuzhi Ji, Huizi Sha, Fanyan Meng, et al.
Medcomm|July 8, 2024
Liposome-based in situ antigen-modification strategy for "universal" T-cell-receptor engineered T cell in cancer immunotherapyQin Wang, Rui Peng, Haoyue Qi, et al.
Frontiers in Immunology|January 23, 2026
Correction: Tumor-penetrating peptide boosts bispecific T-cell engager antitumor efficacy for the pancreatic cancerLu Zou, Jingjing Chen, Xinyuan Bai, et al.
Pageof 9

Showing results (51-60 of 88) with videos related to

Sort By:
Pageof 9
Frontiers in Immunology|December 31, 2025
Tumor-penetrating peptide boosts bispecific T-cell engager antitumor efficacy for the pancreatic cancerLu Zou, Jingjing Chen, Xinyuan Bai, et al.
Frontiers in Oncology|June 21, 2021
Identification of a Glypican-3 Binding Peptide From a Phage-Displayed Peptide Library for PET Imaging of Hepatocellular CarcinomaJiayao Yan, Xiaoxiao Yu, Xiaotong Chen, et al.
Human Vaccines & Immunotherapeutics|February 22, 2023
Biomarkers for predicting tumor response to PD-1 inhibitors in patients with advanced pancreatic cancerXin Qiu, Zhan Shi, Fan Tong, et al.
Materials Today. Bio|June 23, 2022
In situ gelatinase-responsive and thermosensitive nanocomplex for local therapy of gastric cancer with peritoneal metastasisXinyue Wang, Jiahui Gao, Chunhua Li, et al.
Cancer Science|September 19, 2021
Tumor eradicated by combination of imiquimod and OX40 agonist for in situ vaccinationYanhong Chu, Rutian Li, Lingyu Qian, et al.
Journal for Immunotherapy of Cancer|May 14, 2021
Bifunctional iRGD-anti-CD3 enhances antitumor potency of T cells by facilitating tumor infiltration and T-cell activationShujuan Zhou, Fanyan Meng, Shiyao Du, et al.
Cellular Immunology|June 16, 2018
Activation and propagation of tumor-infiltrating lymphocytes from malignant pleural effusion and ascites with engineered cells for costimulatory enhancementQiuping Xu, Jie Shao, Shu Su, et al.
Oncology Reports|January 8, 2021
[Corrigendum] Tumor‑penetrating peptide fused EGFR single‑domain antibody enhances radiation responses following EGFR inhibition in gastric cancerFuzhi Ji, Huizi Sha, Fanyan Meng, et al.
Medcomm|July 8, 2024
Liposome-based in situ antigen-modification strategy for "universal" T-cell-receptor engineered T cell in cancer immunotherapyQin Wang, Rui Peng, Haoyue Qi, et al.
Frontiers in Immunology|January 23, 2026
Correction: Tumor-penetrating peptide boosts bispecific T-cell engager antitumor efficacy for the pancreatic cancerLu Zou, Jingjing Chen, Xinyuan Bai, et al.
Pageof 9